ABSTRACT

Background and objectives: Esophageal cancer is the eighth most common type of cancer in the world. Considering the adverse effects of anticancer drugs and the emergence of chemotherapy resistance, plant-derived extracts and their constituents could be a valuable source of novel anticancer drugs. In this study, we investigated cytotoxic effects of Juniperus excelsa leaf extract on esophageal cancer cell line KYSE-30 and healthy fibroblast cells (HU02 cells).

Methods: KYSE-30 cells and HU02 cells were cultured in DMEM medium. The cells were treated with different concentrations (1, 10, 100, 500 μg/ml) of the J. excelsa leaf extract for 24 and 48 hours. The cytotoxic effects of the extract were assessed using the MTT assay. Data were analyzed using SPSS (version 19) and GraphPad Prism 5.

Results: According to results of the MTT assay, the Juniperus excelsa's leaf extract exerted significant cytotoxic effects on esophagus cancer cell line (KYSE-30) and healthy fibroblast cells (HU02) in a time- and dose-dependent manner (P<0.05).

Conclusion: The J. excelsa leaf extract has cytotoxic effects against KYSE-30 esophageal cancer cells while causing lesser toxicity on healthy fibroblast cells. Our findings suggest that the potential anticancer effects of this extract should be further exploited in future studies.

Keywords: Cytotoxic, MTT, HU02, Kyse-30, Juniperus excelsa.
INTRODUCTION

Esophageal cancer (EC) is the eighth most common type of cancer and the sixth cause of cancer deaths in the world (1). According to the reports of the World Health Organization (WHO), nearly 400,000 people die of EC every year (1). About 51,000 cancer cases are diagnosed in Iran every year, of which 6500 cases are affected by EC (3). The two most common forms of esophageal cancer are squamous cell carcinoma and adenocarcinoma with a 5-year survival rate of less than 10% (4). Factors including opium and narcotic drugs use, acid reflux, drinking alcohol and hot beverages, vegetarianism, selenium deficiency, viral and Helicobacter infections and genetic susceptibility are considered as risk factors of EC (5). Given the adverse effects of anticancer drugs and the emergence of chemotherapy resistance, much emphasis has been put on discovering novel complementary and alternative therapies with less side effects and a high therapeutic efficacy (6-7). Evidence suggests that some secondary metabolites of plants may be an incredible source of compounds with potential anticancer effects (8). Juniperus excelsa is a coniferous plant from the Cupressaceae family that grows wild in Asia (9). The leaf of this plant is rich in monoterpene hydrocarbons such as α-pinene, β-pinene, myrcene, sabine, limonene, ethyl acetate, β-carotene and flavonoids (9). The plant has been used in traditional medicine for wound/scars healing and treatment of edema, kidney disease, rheumatism, ulcerative colitis, toothache, etc. (9-11). To investigate the potential anticancer properties of this plant, we investigated the cytotoxic effects of J. excelsa extract on an EC cell line (KYSE-30) and normal fibroblast cells (HU02).

MATERIALS AND METHODS

Both cell lines were bought from the cell bank of the Pasteur Institute of Iran (Tehran, Iran). Dulbecco’s Modified Eagle Medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco (USA), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was bought from Merck (Germany). Two kg J. excels leaves and twigs were collected from Bandar Abbas (Iran) in April 2016. Once rinsed, the leaves and twigs were shade-dried at room temperature and then powdered using an electric mill. Next, the plant powder was mixed with 250 ml of pure methanol on a shaker for 24 hours, at 40-50 °C. The mixture was passed through a Whatman filter paper and then placed in a rotary evaporator. The obtained extract was passed through a Whatman filter paper and then poured in a special essence container. To prepare a concentration range, the extract was diluted with various volumes of the medium without serum. After being passed through a Millipore filter (pore diameter of 0.22 μm), the prepared concentrations of the extract were stored in a refrigerator until use. KYSE-30 and HU02 cells were cultured in a T25 flask containing DMEM with 10% FBS, 100 μg/ml penicillin and 100 μg/ml streptomycin (Gibco, Germany). The flask was incubated at 37 °C, 5% CO₂ and in 95% humidity for 4 hours. The cells were passaged twice and were trypsinized. A cell suspension (10⁵ cells/ml) was prepared and poured in wells of a 96-microwell plate. Later, various concentrations (1, 10, 100, and 500 μg/ml) of the J. excelsa extract were added to each well. The microplate was incubated at 37 °C for 24 and 48 hours (Figure 1). Cytotoxic effects of the extract on KYSE-30 and HU02 cells and the optimum concentration of the extract were evaluated using the MTT assay. The assay relies on the reduction of MTT, a yellow water-soluble tetrazolium dye, primarily by mitochondrial dehydrogenases, to purple colored formazan crystals (12). There is a direct relationship between the produced formazan crystals and the population of live cells.

After 24 and 48 hours of incubation, supernatant was discarded and 100 μl of DMEM medium containing 100 mg/ml MTT solution were added to each well. The microplate was incubated for 4 hours at 37 °C, 5% CO₂ and in 95% humidity. After 5 to 10 minutes, supernatant was discarded and absorbance at 540-690 nm was read by an ELISA reader (Emax® Endpoint). This experiment was repeated five times. The half maximal inhibitory concentration (IC₅₀) was calculated using the GraphPad Prism 5 software. Data were analyzed by SPSS software (version 19) using two-way ANOVA and Bonferroni correction. Data were expressed as mean ± standard deviation. P-values less than 0.05 were considered as statistically significant.
RESULTS

Based on the results of the MTT assay, the mean IC$_{50}$ of the J. excelsa extract against KYSE-30 cancer cells was 118.5 µg/ml after 24 hours and 21.85 µg/ml after 48 hours. Increasing the incubation time from 24 hours to 48 hours significantly increased the inhibitory effects of the extract against these cells (P<0.05). After 24 hours of incubation, concentrations of 1, 10, 100 and 500 µg/ml of the extract exerted cytotoxic effects on 97.57%, 88.04%, 68.92% and 57.97% of the KYSE-30 cells, respectively. After 48 hours, the extract at concentrations of 1, 10, 100 and 500 µg/ml showed cytotoxic effects on 97.03%, 77.18%, 66.56% and 53.87% of the KYSE-30 cells, respectively (Figure 2). Furthermore, the mean IC$_{50}$ of the J. excelsa extract against HU02 fibroblast cells was 77.05 µg/ml after 24 hours and 9.82 µg/ml after 48 hours. Increasing the incubation time from 24 hours to 48 hours significantly increased the inhibitory effects of the extract against these cells (P<0.05). After 24 hours of incubation, the extract at concentrations of 1, 10, 100 and 500 µg/ml showed cytotoxic effects on 93.35%, 82.81%, 63.11% and 39.22% of the fibroblast cells (HU02 cells), respectively. After 48 hours, concentrations of 1, 10, 100 and 500 µg/ml of the extract exerted cytotoxic effects on 91.05%, 70.63%, 45.90% and 30.52% of HU02 cells (Figure 3 and Table 1). The results show that increasing the concentration of the extract significantly decreases the number of viable cells (P<0.05).
Table 1- Percentage viability of the KYSE-30 cancer cells and normal fibroblast cells (HU02) following 24 and 48 hours of incubation with various concentrations of the J. excelsa extract

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Concentration of extract (µg/ml)</th>
<th>Viability after 24h</th>
<th>Viability after 48h</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>KYSE-30</td>
<td>1</td>
<td>93.35±2.30</td>
<td>91.05±2.30</td>
<td>P&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>82.81±12.18</td>
<td>70.63±12.18</td>
<td>P&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>63.11±17.20</td>
<td>45.90±17.20</td>
<td>P&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>500</td>
<td>39.22±8.69</td>
<td>30.52±8.69</td>
<td>P&gt;0.05</td>
</tr>
<tr>
<td>HU02</td>
<td>1</td>
<td>97.57±9.53</td>
<td>97.03±9.53</td>
<td>P&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>88.04±10.86</td>
<td>77.18±10.86</td>
<td>P&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>68.92±2.36</td>
<td>66.56±2.36</td>
<td>P&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>500</td>
<td>57.97±4.09</td>
<td>53.87±4.09</td>
<td>P&gt;0.05</td>
</tr>
</tbody>
</table>

DISCUSSION

Numerous studies have been carried out on the medicinal properties of plants and their extracts (13-17). The potential favorable effects of such extracts could be attributed to the presence of compounds such as terpenes, flavonoids, polyphenols and other secondary metabolites in these extracts (8). Numerous studies have investigated the cytotoxic effects of various plant extracts and their constituents on different gastric and esophageal cancer cell lines. According to these studies, the cytotoxic effects of these compounds can be attributed to their high flavonoid and phenolic content and antioxidant properties (13-17). Another study showed that the water-soluble Cuminum cyminum extract has anticancer effects on human colon cancer cell line SW742 (18). In another study, low concentrations of Ecballium elaterium extract exhibited cytotoxic effects on KYSE-30 cells. In addition, this effect was increased by extending the incubation time (19). In a study on alcoholic extracts of Avocado’s fruit and leaves, cytotoxic activity of the extract on esophageal cancer cells (KJSE cells) was attributed to the presence of phytochemicals, which inhibits cell growth by blocking intratumoral growth signals and increasing activity of intracellular oxygen radicals (20). In the present study, we evaluated the toxic and anticancer effects of the J. excelsa extract on KYSE-30 and HU02 cells. The mean IC<sub>50</sub> of the J. excelsa extract against KYSE-30 cancer cells was 118.5 µg/ml after 24 hours and 21.85 µg/ml after 48 hours. Furthermore, the inhibitory effects of the extract were more notable against KYSE-30 cancer cells than against healthy fibroblast cells (HU02). A previous study reported that the J. excelsa extract have anti-proliferative and inhibitory effects against hepatoma cell line HepG2 (21). In another study, the cytotoxic effects of the J. excelsa extract against human colon cancer cell line (LNCaP), KB-V (+VLB) and KB-V (- . VLB) were attributed to the presence of diterpenes and sesquiterpenes (22). In another study, extracts of Juniperus foetidissima and Juniperus Sabina showed cytotoxic activity against HeLa cells. The extract of J. foetidissima also showed inhibitory effects on MDAMB468 (human breast adenocarcinoma) cells but not against KB (human epidermoid carcinoma) cells (23). Muto et al. revealed that Juniperus taxifolia leaf extract has cytotoxic effects against human leukemia cell line HL-60 (24). In a study by Emami et al., extracts from J. foetidissima leaves and fruit exhibited antioxidant and anticancer activities (25). The extract from J. excelsa leaves is rich in monoterpenic hydrocarbons, oxygen-containing monoterpene sesquiterpenes, oxygen-containing sesquiterpenes and flavonoids with antioxidant properties (9,25). The antioxidant properties of flavonoids are exerted via complex formation with metal ions and activation of peroxisome proliferator-activated receptors, which inhibits COX-2 expression and oxidation reactions in lipids and other molecules (14,26-29). Therefore, they can prevent cancer progression by disrupting biological activities that can negatively affect the control of cell cycle, cell proliferation and cell differentiation (14, 26-29). The J. excelsa extract also contain α-pinene and β-pinene that can exert antioxidant and proapoptotic effects and promote tumor suppressor activity by increasing the expression of P53 (17, 26). On the other hand, some polyphenolic antioxidants can interact with nitric oxide synthase (26) and disrupt mitochondrial respiratory chain, thereby increasing production of caspas 3, 8 and 9.
and inducing apoptosis in cancer cells (12).

CONCLUSION

Our findings show that the J. excelsa can exert inhibitory effects against KYSE-30 cancer cells and healthy fibroblast cells in a time- and dose-dependent manner. However, the therapeutic potential of this extract for treatment of esophageal cancer requires further investigation.

ACKNOWLEDGEMENTS

We are thankful to the Alzahra University.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest regarding the publication of this article.

REFERENCES


